

Freedom of Information Request	FOI 23-421	11 October 2023
--------------------------------	------------	-----------------

## Your request

You requested the following:

1. Does your trust treat myeloproliferative neoplasms? If not, which other trust do you refer these patients to?
2. Please provide the total number of patients treated in the last 6 months for:
  - Polycythaemia Vera (ICD10 code D45)
  - Myelofibrosis (ICD10 code D47.4)
  - Myelofibrosis (ICD10 code D47.4) patients aged 65 and older
3. How many patients were treated in the past 6 months (for any disease) with:
  - Ruxolitinib
  - Fedratinib
4. Of the patients treated in the past 6 months with Ruxolitinib, how many patients had a diagnosis for:
  - Polycythaemia Vera (ICD10 code D45)
  - Myelofibrosis (ICD10 code D47.4)
5. How many myelofibrosis (ICD10 code D47.4) patients has your trust diagnosed in the past 3 years?
  - Of these patients, how many were treated in the past 6 months with Hydroxycarbamide?
  - Of these patients, how many were treated in the past 6 months with Interferon therapy?
  - Of these patients, how many have received no active treatment in the past 6 months?
6. Does your trust participate in any clinical trials for the treatment of myelofibrosis? If so, can you please provide the name of each trial along with the number of patients taking part.

## Our response

1. Yes

For questions 2 to 5, we are not able to provide information on individual treatment plans as it is not recorded centrally. To comply with your request, we would need to review every patient record which we have established would take in excess of 18 hours to undertake and therefore exceeds the appropriate costs limit under Section 12 of the Freedom of Information

Act 2000, which is currently £450. This is not an exemption which requires us to consider the application of the public interest test.

6. No